As you said JD, Bioasis can already get drugs into the brain without all the fuss of FUS, so it's beyond my comprehension why BTI keeps delaying a Clinical Phase 1. This way at least they can prove safety and with that in hand, xB3 can be taken advantage of by the likes of Sunnybrook and other Cancer Medical (experimental) Centres to put Bioasis on the map.  And if xB3 can cross the BBB safely that will certainly give the stock a lift it badly needs. In a nutshell, why is this not being done?

Koo